Abstracts presented at the 19th International Workshop on Co‑morbidities and Adverse Drug Reactions in HIV Milan, Italy, 23–25 October 2017 cover page.indd 1 25/10/2017 10:08:58 ORGANIZING COMMITTEE Chairs for 2017 Todd T Brown Johns Hopkins University, Baltimore, MD, USA Andrew Carr St Vincent’s Hospital, Sydney, Australia Giovanni Guaraldi University of Modena, Modena, Italy Jacqueline Capeau Faculty of Medicine Saint Antoine, INSERM, Paris, France David Cooper University of New South Wales, Sydney, Australia Stefan Mauss Center for HIV and Hepatogastroenterology, Düsseldorf, Germany Kathleen Mulligan University of California at San Francisco, CA, USA Peter Reiss Academic Medical Center, Amsterdam, the Netherlands Morrie Schambelan University of California at San Francisco, CA, USA SCIENTIFIC COMMITTEE Judith Currier University of California, Los Angeles, CA, USA Michael Dubé University of Southern California, Los Angeles, CA, USA Julian Falutz Immune Deficiency Treatment Center, Montreal General Hospital, Montreal, Canada Steve Grinspoon Massachusetts General Hospital, Boston, MA, USA Carl Grunfeld University of California Medical Center, San Francisco, CA, USA Giovanni Guaraldi University of Modena, Modena, Italy Donald Kotler Columbia University, New York, NY, USA Jules Levin The National AIDS Treatment Advocacy Project, New York, NY, USA Jens Lundgren University of Copenhagen, Hvidovre, Denmark Esteban Martínez IDIPAPS - Hospital Clinic, University of Barcelona, Barcelona, Spain Graeme Moyle Chelsea and Westminster Hospital, London, UK Pablo Tebas University of Pennsylvania, Philadelphia, PA, USA Sharon Walmsley University Health Network, Toronto, Canada Kevin Yarasheski Washington University, St Louis, MO, USA PLENARY SPEAKERS Stefan D Anker University Medical Center Göttingen, Göttingen, Germany Juliet Compston University of Cambridge, Cambridge, UK David Cooper University of New South Wales, Sydney, Australia Stefano Del Prato University of Pisa, Pisa, Italy Sven Enerback University of Gothenburg, Gothenburg, Sweden ORGANIZING SECRETARIAT International Medical Press Admiral House 76–78 Old Street London, EC1V 9AZ, UK Tel: +44 20 7398 0700 Fax: +44 20 7398 0701 www.intmedpress.com/comorbidities [email protected] 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV Prelims_2017_web.indd 5 25/10/2017 10:17:36 ABSTRACT CONTENTS PAGE TITLE AND PRESENTING AUTHOR ABSTRACT ORAL PRESENTATIONS Session 1 A3 Frailty predicts recurrent but not single falls 10 years later in HIV+ and O01 HIV- women A Sharma A5 Influence of HIV infection on the development of sarcopenia in O02 HIV-infected subjects P Echeverría A6 Longitudinal analysis of quality of life (QOL) in HIV-positive and O03 HIV-negative subjects enrolled to the UPBEAT (Understanding the Pathology of Bone Disease in HIV Infected Subjects) cohort study after 5 years of follow-up E Alvarez Session 2 A7 Patterns of co-occurring comorbidities in people living with HIV O04 D De Francesco A8 Changes in lipid parameters, body fat, bone mineral density and O05 inflammation/immune activation markers in middle-aged HIV-infected patients with viral suppression treated with etravirine/raltegravir – results at week 48 of the ANRS163-ETRAL trial J Capeau A9 African mitochondrial DNA haplogroup L2 is associated with increased O06 b-cell function and protection from incident diabetes mellitus in HIV-seropositive African American women TT Brown Session 3 A10 Effect of vitamin D supplementation on bone turnover markers (BTMs) O07 during HIV pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) in men who have sex with men (MSM). A matched case-control substudy of CCTG 595 MP Dubé A11 Baseline bone mineral density in a cohort of young HIV-infected women O08 using tenofovir and Depo-Provera F Matovu Kiweewa A12 Relationships between bone density, bone quality and reported fractures O09 within the HIV UPBEAT cohort T McGinty A13 Rate of progression to osteoporosis in a large cohort of HIV-infected O10 subjects A Bonjoch 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xv Prelims_2017_web.indd 15 25/10/2017 10:17:38 PAGE TITLE AND PRESENTING AUTHOR ABSTRACT Session 4 A14 A randomized, double-blinded, placebo-controlled trial of the dipeptidyl O11 peptidase-4 (DPP-4) inhibitor sitagliptin for reducing inflammation and immune activation in treated and suppressed HIV infection: ACTG 5346 MP Dubé A15 Analysis of serum metabolomics parameters associated with carotid O12 intima-media thickness (c-IMT) and inflammation in HIV-infected, never-smoker men, naive of ART or ART-controlled, compared with matched HIV-negative controls J Capeau A16 Prospective analysis of lipid compositional changes with antiretroviral O13 therapy (ART) and immune activation in persons living with HIV NT Funderburg A17 HIV disease progression is controlled by cell cholesterol homeostasis O14 dysregulation in antigen presenting cells G Rappocciolo Session 5 A18 HIV increases renal complications, hospitalization and mortality in O15 diabetes mellitus G Lui A19 Utility of chronic kidney disease (CKD) risk prediction scores and the O16 changing prevalence of CKD in HIV-positive individuals JM Trevillyan A20 Investigating the effect of antiretroviral switch to tenofovir alafenamide O17 on lipid profiles in people living with HIV within the UCD ID Cohort A Lacey Session 6 A21 Tenofovir exposure is associated with low bone mineral density but not O18 increased trabecular bone score R Bedimo A22 Bone density, microarchitecture and tissue quality after 48-weeks and O19 96-weeks of treatment with tenofovir disoproxil fumarate R Güerri-Fernández A23 Impact of antiretroviral treatment containing tenofovir difumarate on O20 telomere length attrition in a prospective cohort of aviraemic HIV-infected participants R Montejano A25 A randomized comparison of integrase inhibitors with TDF/FTC on renal O21 markers G Moyle Session 7 A26 Associations between subcutaneous fat density and metabolic and O22 inflammatory biomarkers differ by HIV serostatus and are independent of fat quantity JE Lake xvi Programme & Abstracts Prelims_2017_web.indd 16 25/10/2017 10:17:38 PAGE TITLE AND PRESENTING AUTHOR ABSTRACT A27 Intrahepatic triglyceride is more strongly associated with insulin-resistant O23 glucose metabolism than visceral adiposity in HIV, and is improved with tauroursodeoxycholic acid treatment DN Reeds A28 Alterations of adipose tissue induced by HIV or SIV infection: Tat and O24 Nef-induced senescence and fibrosis J Gorwood POSTER PRESENTATIONS Adipocyte biology, insulin resistance & lipid metabolism A31 Compromised macrophage-mediated HIV trans infection of CD4+ T cells P01 in non-progressors is linked to DC-SIGN expression and lipid raft dissociation DC DeLucia A32 Evaluation of lipid levels in HIV-infected patients after being switched P02 from a tenofovir disoproxil fumarate to a tenofovir alafenamide containing-regimen in a clinic in Puerto Rico I Melendez-Rivera A33 Underdiagnosis and suboptimal care of diabetes mellitus in a French P03 HIV-infected cohort in 2016 L Slama A34 MicroRNA expression profiling in a couple of monozygotic twins P04 discordant for HIV infection: focus on the potential lipodystrophy biomarkers N Squillace Aging & associated disorders A35 Impact of a mobile health application (‘App’) on clinical outcome and P05 satisfaction of older HIV-infected patients as an emerging tool for care, education and prevention P Echeverría A36 Aging in HIV-infected and uninfected populations: a comprehensive P06 geriatric assessment P Echeverría A37 Compression of frailty at an older age an aging population infected with P07 HIV: a ‘geriatric-HIV’ modelling study G Guaraldi A38 Internet illiteracy as a barrier to use of a web-based health promotion P08 resource among elderly HIV patients G Guaraldi A39 Feasibility and long-term assessment of physical and behavioural P09 functioning among older adults with HIV G Guaraldi A40 HIV and aging in Lebanon: an exploratory study of unmet health needs P10 among a cohort of PLHIV NM Melhem 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xvii Prelims_2017_web.indd 17 25/10/2017 10:17:38 PAGE TITLE AND PRESENTING AUTHOR ABSTRACT Body composition A41 Prevalence and predictors of sarcopenia in a large HIV-infected cohort P11 characterized with nutrition and physical activity data G Guaraldi A42 Trunk fat increases consistently in HIV-infected adults on antiretroviral P12 therapy, with patterns differing by sex JE Lake A43 Visceral adiposity is increased in the setting of HIV infection but is not P13 associated with increased inflammation BS Taylor Bone metabolism & toxicities A45 The relationship between physical activity and bone mineral density: P14 results from the SATURN HIV Study JD Perazzo A46 Polypharmacy and osteopenia/osteoporosis in HIV infection: are drugs P15 other than antiretrovirals implicated? N Squillace Cardiovascular disease A47 ApoB/ApoA ratio is associated with subclinical atherosclerosis in treated P16 HIV patients M Arnedo A48 Decreased oxidative stress and endothelial dysfunction: potential P17 mechanisms for cardioprotective effect of atazanavir R Bedimo A49 Determinants of uncontrolled blood pressure in treated hypertensive P18 adults living with HIV F Boccara A50 Nycthemeral blood pressure variation in hypertensive adults living P19 with HIV. Description of non-dipping hypertension F Boccara A51 Usefulness of 24-h ambulatory blood pressure monitoring in adults living P20 with HIV F Boccara A52 Switching from boosted protease inhibitors (PI/r) to dolutegravir (DTG) in P21 virologically suppressed HIV-infected patients with high cardiovascular risk: 48-week effects on subclinical cardiovascular disease E Martinez A53 Contribution of aggressive cardiovascular risk factor screening to detect P22 vascular peripheric disease and coronaropathy in HIV-treated patients L Slama A54 Use of lipid-lowering therapy (LLT) and achievement of recommended P23 targets in an aging cohort of people living with HIV A Lacey xviii Programme & Abstracts Prelims_2017_web.indd 18 25/10/2017 10:17:38 PAGE TITLE AND PRESENTING AUTHOR ABSTRACT Clinical management of ADRs A55 Discontinuation of dolutegravir- and elvitegravir-containing cART in the P24 Netherlands; incidence rates and risk factors PDJ Bollen A56 Aging with HIV: a new challenge to manage polypharmacy and P25 antiretroviral therapy – a nationwide survey of cART-related adverse drug reactions C Allavena A57 Safety analysis of German real-life cohort WIP shows low rates of P26 neuropsychiatric events leading to discontinuation of raltegravir therapy B Funke A58 Assessing potentially inappropriate prescribing in community-dwelling P27 older HIV patients using the STOPP-START criteria G Guaraldi A59 Pharmacist review of medications for HIV-positive people seen in general P28 practice (PROM-GP) KF Mackie A60 Occurrence of hypersensitivity reaction and hepatotoxicity in patients P29 receiving integrase inhibitors: results from the EuroSIDA study L Shepherd A61 Failure of antiretroviral therapy (ART) in Australian adults is mainly due P30 to ART toxicity KJ Siefried A62 Polypharmacy of concomitant medications in HIV-infected Australian P31 adults is common, and associated with adverse effects KJ Siefried A63 Socioeconomic and psychosocial factors are associated with suboptimal P32 outcomes in HIV-infected adults: a case-control analysis KJ Siefried Liver disease & hepatotoxicity A65 Clinical, immunological and virological evolution in HIV/HCV-coinfected P33 patients 12 and 24 weeks after direct-acting antiviral agents treatment TF Aiello A66 HIV infection does not affect hepatic steatosis or fibrosis P34 DP Kotler A67 Incidence of didanosine-related liver disease in HIV-positive individuals P35 in British Columbia SA Lother A68 Does antiretroviral therapy affect ALT levels in HIV/HCV-coinfected patients P36 after SVR (GECCO)? S Mauss A69 An audit of coinfected patients with HIV, treated for hepatitis C in 1 year P37 at a single UK centre L Taylor 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xix Prelims_2017_web.indd 19 25/10/2017 10:17:38 PAGE TITLE AND PRESENTING AUTHOR ABSTRACT Other co-morbidities (cancer, neurocognitive disorders and renal toxicities) A71 Gender differences in ART treatment outcomes in Taiwan – a matched P38 case control study in a tertiary care hospital C-C Shih A72 Case study: cutaneous vasculitis in the setting of dolutegravir initiation P39 VJ Cornelisse A73 Validity of the ViovFit2 activity tracker in measuring steps in community P40 dwelling HIV-infected geriatric patients G Guaraldi A74 Respiratory symptoms, lung structural and functional abnormalities in a P41 cohort of never-smoking HIV-infected patients: comparison with HIV-negative controls G Guaraldi A75 Neurocognitive impairment is associated in virally suppressed P42 HIV-infected persons who are aging G Guaraldi A76 Pancreatic insufficiency in patients with long-lasting HIV infection P43 S Grützmeier A77 Chronic kidney disease in Australian HIV-infected patients: analysis of P44 the Australian HIV Observational Database CC O’Connor A78 Real-life experience of switching from integrase strand transfer P45 inhibitors (INSTIs) to darunavir/cobicistat (DRV/c), because of toxicity or intolerance A Rodríguez-Da Silva A79 Abacavir usage patterns and hypersensitivity reactions (HSR) in the P46 EuroSIDA cohort A Roen A80 Prevalence and risk factors of HIV neurocognitive disorders (HAND) in a P47 Spanish HIV cohort M Sanmartí xx Programme & Abstracts Prelims_2017_web.indd 20 25/10/2017 10:17:38 ORAL PRESENTATIONS Orals.indd 1 04/10/2017 09:19:07 Orals.indd 2 04/10/2017 09:19:07